As of June 2026, OGN's trailing twelve months (TTM) EPS stands at $0.94, according to the latest financial reports. In 2025, the company recorded an earnings per share (EPS) of $0.72, which represents a decrease compared to its EPS of $3.36 in 2024. OGN reported an EPS of $0.56 for the quarterly report ending on Mar 31, 2026.
For 2025, Organon's EPS was $0.72, a decrease of 78.6% from $3.36 in 2024. For the quarter ending Mar 31, 2026, the EPS was $0.56, showing a 64.7% increase from the same quarter last year. The trailing twelve months (TTM) EPS as of March 2026 is $0.94. In 2024, the annual EPS was $3.36, showing a decrease of 16.2% from 2023.
Over the last 12 months, Organon has registered an EPS growth of 64.7% (YoY, quarterly). Over a three-year span, the company had an average EPS growth of -41.6% per year. Over the last 5 years, the company had an average EPS growth rate of -39%.
| Stock name | Price to Earnings | EPS grwoth 1Y | EPS grwoth 3Y | EPS grwoth 5Y |
|---|---|---|---|---|
| OGN Organon & Co | 14.26 | -78.6% | -41.6% | -39% |
| OPK Opko Health Inc | N/A | -275% | N/A | N/A |
| ORGO Organogenesis Holdings Inc | N/A | 1,700% | 10.1% | 0% |
All data is based on quarterly TTM periods, unless otherwise specified.